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S U M M A R Y
Objectives: The purpose of this review was to compare the mortality rates for hepatocellular carcinoma
(HCC) among hepatitis B surface antigen (HBsAg)-seropositive renal transplant (RT) patients versus
HBsAg-seropositive persons of the general population.
Methods: A comprehensive search was performed to identify cohort studies of HBsAg-seropositive RT
patients with at least 4 years of follow-up. Data were analyzed as outlined below. HCC was a rare event in
regions of low and intermediate seroprevalence of HBsAg. Subsequently, studies from low and
intermediate seroprevalence areas were analyzed separately from those of high seroprevalence areas.
Results: Thirty-one retrospective studies that followed 1277 seropositive RT patients were identiﬁed for
inclusion. The studies were pooled and compared to four different general population studies that
included 12 558 seropositive persons using Poisson methods. The mortality rate of HCC was increased in
low and intermediate seroprevalence areas (RR 7.67, 95% conﬁdence interval (CI) 3.93–15.0; RR 9.92, 95%
CI 5.38–18.3). In high seroprevalence areas, the mortality rate of HCC was increased compared to one
population study, but not another (RR 2.76, 95% CI 1.64–4.63; RR 1.02, 95% CI 0.61–1.69).
Conclusions: Mortality due to HCC was increased in low and intermediate seroprevalence areas, but the
evidence was inconclusive for high seroprevalence areas.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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It is well known that the rates of some types of cancer are
increased among transplant recipients.1,2 The compromised ability
to resolve infections is thought to selectively increase cancers
caused by infectious agents.2 Hepatitis B virus (HBV) and hepatitis
C virus (HCV) are both known to cause hepatocellular carcinoma
(HCC) in the general population.3 The rates of HCC among renal
transplant (RT) recipients have been generally reported to be
increased compared to non-transplant persons of the general
population.4–7 However, these studies simply compared the rates
of HCC among the overall RT cohorts with the overall general
population. Subsequently, the reported increases may simply
reﬂect differences in the prevalence of risk factors, such as
infection with HBV or HCV. It has not been speciﬁcally assessed
whether immunosuppressive therapy increases the rate of HCC
among HBV-infected persons. Therefore, it was decided to perform
a systematic review of the subject.* Tel.: +1 519 824 9875; fax: +1 519 824 3947.
E-mail address: c.brianblackadar@hotmail.com.
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http://dx.doi.org/10.1016/j.ijid.2012.08.002Few reports on the incidence of HCC among RT patients have
been published, whereas reports of mortality from HCC are much
more common. (HCC is usually not diagnosed until the advanced
stages. Subsequently, incidence rates are only slightly higher than
the mortality rates.8,9) Therefore it was decided to perform a
systematic search of the literature for longitudinal studies
reporting mortality due to HCC among hepatitis B surface antigen
(HBsAg)-seropositive RT patients, and to compare these with
longitudinal studies of mortality rates for HCC among HBsAg-
seropositive persons of the general population.
HCC is rare among HBsAg-seropositive RT patients in developed
countries. Mortality due to liver failure is reported much more
frequently. Consequently, most studies have included mortality
due to non-malignant liver diseases (NMLD). These studies were
also analyzed.
The effect of HBV infection on the overall mortality of RT
patients has been a long-standing controversy.10–12 Some studies
have reported that HBsAg-seropositive RT patients have strongly
increased mortality rates due to increased rates of liver disease.
Other studies have reported no increase in mortality among
HBsAg-seropositive versus seronegative RT patients. Fabrizi et al.
published a meta-analysis of this in 2005.13 However, some
consider the subject to remain controversial.14,15 A number of theses. Published by Elsevier Ltd. All rights reserved.
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causes for HBsAg-seropositive versus seronegative RT patients. It
was decided that an independent analysis would provide a useful
contribution to the literature, and so these studies were also
analyzed.
In summary, this review compares various mortality rates for
HBsAg-seropositive RT patients with (1) HBsAg-seropositive non-
transplant persons of the general population and (2) HBsAg-
seronegative RT patients.
2. Methods
2.1. Search strategy
This review was prepared by searching Medline, EMBASE, and
Web of Science for ‘‘transplant’’, ‘‘transplantation’’, ‘‘renal’’,
‘‘kidney’’, ‘‘HBV’’, ‘‘hepatitis B virus’’, ‘‘hepatocellular carcinoma’’,
‘‘HCC’’, ‘‘liver cancer’’, and ‘‘long-term’’. The search focused on the
period of 1980 until June 15, 2012, as the earliest case reports of
HCC among RT patients only emerged in the early 1980s.16,17
Reference lists were searched for additional articles, including
studies published in the 1970s that had adequate follow-up and
indicated whether deaths due to HCC occurred. The inclusion
criteria were designed to include as many studies as possible.
Studies were simply required to: state the number of HBsAg-
seropositive RT recipients in the cohort, follow at least 10 HBsAg-
seropositive RT patients, state the total person-years (or mean
duration) of follow-up, and indicate the number of deaths due to
HCC. Numerous studies have reported that the risk of HCC only
increases 5–10 years after transplantation,18–20 so studies with less
than 4 years of follow-up were excluded. Studies of patients who
received antiviral therapy were excluded. An e-mail was sent to the
authors of studies published after 2005 that met the inclusion
criteria, in order to query whether antiviral therapy was used.
(Antiviral therapy only became widely used in the late 1990s.
Therefore most of the follow-up from studies published beforefull te xt articles
(n =  55
EMBASE Web  of  Scien ce 
No analysis  for  HB sAg  (n =  285)
Selective analysis  of  patients
(only reported HB V status of 
patients who  died  of  HCC or 
NMLD)  (n =  15)
Mortali ty due to  HCC not repo rted 
(n =  12)
Selectively reported follow -up  of 
patients with  li ver d ysfunction or 
cirrho sis  (n = 5)
Included a 
(n =  3
Figure 1. Flow diagram of the study selection process. (aUnusual follow-up (1), plagiarism
patients untreated (1), received correspondence that required the studies to be exclud2005 was considered to be for untreated patients unless indicated
otherwise.) Some studies reported mortality due to liver cancer
without indicating whether the cancer was HCC. Since HCC is the
most prevalent type of liver cancer in most parts of the world,
cancers designated as ‘liver cancer’ were recorded as HCC for this
analysis. Studies that did not test for HCV were included. HBV/
HCV-co-infected patients were also included. Co-infection with
human immunodeﬁciency virus (HIV) was an exclusion criterion.
Studies that followed children were excluded because they would
be predicted to have lower rates of HCC. Studies that followed
cohorts of cirrhotic patients and studies of patients with persistent
abnormalities of serum liver function indicators were also
excluded because they would be expected to have increased rates
of HCC.21 Eligible studies generally included all HBsAg-seroposi-
tive RT patients transplanted at a center during a speciﬁc time
period. They were then compared to large cohorts of patients who
were HBsAg-seropositive, but otherwise generally healthy.
2.2. Inclusion criteria
The full texts of 553 articles were retrieved. The strategy to
identify eligible studies began with scanning the articles for
analysis of HBsAg. Many studies were quickly excluded at this
stage. Studies that mentioned HBsAg analysis were further
scanned for >10 seropositive patients in the cohort and >4 years
of follow-up. Studies identiﬁed to have >10 seropositive patients
and >4 years of follow-up were read carefully to determine
whether mortality was described in sufﬁcient detail for inclusion.
It was not deemed necessary to speciﬁcally state whether HCC
occurred. A study that stated three deaths from cancer occurred,
one breast, one prostate, and one colon, was eligible because it
could be deduced that no mortality due to liver cancer occurred.
Studies that focussed on mortality without describing speciﬁc
causes of death were excluded. Further details of the selection
strategy are provided in Figure 1 and below in the Results section.
The studies identiﬁed for inclusion10,22–57 are described in Table 1. retrieved
3)
PubMed Referen ce li sts
Reviews (n =  62)
<10 pat ient s (n =  37)
<4 years  follow -up  (n =  35)
Length of  follow -up  not  repo rted 
(n =  35)
Duplicate  pub licat ion s (n =  25)
rticles
1)
Variou s (n =  11)a
 (1), HBeAg-seropositive patients were treated with antivirals, leaving the healthier
ed (5); see results section for details.)
Table 1
Characteristics of studies included in analysis
Ref. Author (year) Cohort description Maintenance regimen
Countries with low and intermediate seroprevalence of HBsAg
HBsAg-seropositive renal transplant recipients
22 Breitenfeldt (2002) Transplanted from 1978 to 1994 Cs and Aza, 8.4 mg/70 kg/day Pred
23 Correa (2003) Followed from 1993 to 2001 Not stated
24 Aroldi (2005) Transplanted from 1972 to 1989 with a still functioning graft in 1989 <210 mg/70 kg/day Aza, 8 mg/day Pred
25 Lezaic (2008) Transplanted from 1987 to 2001. All HBsAg-pos before transplant ‘‘based on Cs’’, 7 mg/70 kg/day Preda
26 Ridruejo (2010) Transplanted from 1991 to 2008; 2 patients were treated with antiviralsb Various regimens, 0–6 mg/day Predc
27 Shons (1977) Transplanted from 1971 to 1973. HBsAg-pos patients were matched for age and
sex with HBsAg-neg patients. HBsAg-pos before transplant
ALG, 140–210 mg/70 kg/day Aza,
10.5–28 mg/70 kg/day Pred
28 Sengar (1989) Transplanted from 1970 to 1982, survived with transplant for over 1 year 280 mg/70 kg/day Aza, 10–35 mg/day Pred
29 Hiesse (1992) Transplanted from 1970 to 1984 at Biceˆtre Hospital, Paris; most were positive
before transplant
140 mg/70 kg/day Aza, 15 mg/day Pred
30 Berne (1977) Transplanted from 1968 to 1976. All HBsAg-pos before transplant, with no
evidence of active hepatitis before transplant
140–210 mg/70 kg/day Aza, 10.5–28 mg/day
Pred
31 Weir (1985) Transplanted from 1951 to 1976. Only 4 patients were HBsAg-pos before
transplant
Not stated
32 Norder (1989) Transplanted from 1970 to 1986; all survived over 1 year after transplant Aza, Pred, some received ALcG
33 Parfrey (1985) Transplanted from 1967 to 1975, and had a graft functioning after 1 year 100–125 mg/day Aza, 15 mg/day Pred
10 Fornairon (1996) Transplanted from 1967 to 1994 at Necker Hospital Paris 140 mg/70 kg/day Aza, 17.5–350
mg/70 kg/day Pred
34 LeFrancois (1987) Transplanted from 1966 to 1976 at E. Herriot Hospital, and had a graft which
functioned for over 10 years
50 mg/day Aza, 5 mg/day Pred after 20 years
35 Kliem (1994) Transplanted from 1968 to 1992; 61 of 69 patients were HBeAg-pos Cs or Aza, 7.5 mg/day Pred
36 Moreno (1990) Transplanted from 1976 to 1987; grafts functioned for over 1 year Aza or Cs, plus 35 mg/70 kg/day Pred
37 Grekas (1995) Transplanted from 1980 to 1989; grafts functioned for over 1 year; HBsAg-pos and
asymptomatic before transplant
Aza or Cs, or Aza plus Cs and Pred
38 Friedlaender (1989) Transplanted from 1972 to 1986; all patients were HBsAg-pos before transplant Aza, Pred
39 Agarwal (2002) Transplanted from 1981 to 1989, at All India Institute of Medical Sciences,
New Delhi
140–175 mg/70 kg/day Aza,10 mg/day Pred
40 Roy (1996) Transplanted at Vellore India Cs
41 Yagisawa (1997) Transplanted from 1983 to 1994, all HBsAg-pos before transplant Cs plus Pred, some received Aza
42 Teo (2000) Transplanted from 1975 to 1996 Not stated
43 Lawson (1988) Transplanted from 1967 to 1980; grafts functioned for over 1 year 70–140 mg/70 kg/day Aza, 10 mg/day Pred
HBsAg-seropositive population controls
44 Ribes (2006) HBsAg-pos blood donors
45 Crook (2003) HBsAg-pos blood donors
Countries with high seroprevalence of HBsAg
HBsAg-seropositive renal transplant recipients
46 Dusheiko (1983) Transplanted from 1968 to 1981; 14 of 18 patients positive before transplant 50–200 mg/day Aza, 5–25 mg/day Pred
47 Lee (2001) Transplanted from 1984 to 1999 at Taichung Veterans Hospital, Taiwan Cs plus Pred, Aza, or Mmf
48, 49 Huo (2000, 2001) Transplanted between 1986 and 1998 at Taipei Veterans General Hospital, Taiwan 140 mg/70 kg/day Aza, 5 mg/kg/day Cs, Pred
50 Fan (2006)d Transplanted from 1976 to 2004 at Taipei Veterans General Hospital; HBsAg-pos
before transplant; same cohort as Huo et al. (2000, 2001)
51 Ahn (2007) Transplanted from 1979 to 2004 at Yonsei University Severance Hospital; all
positive before transplant; patients with serum evidence of HBV received
lamivudine and were excluded
Aza, Cs, or Tac, plus 10 mg/day Pred
52 Bang (1995) Transplanted from 1985 to 1992, Kang Nam St. Mary’s Hospital; 66 of 79 patients
positive before transplant
Cs plus 14 mg/70 kg/day Pred
53 Sumethkul (2000) Transplanted at Ramathibodi Hospital, Bangkok, Thailand stated Cs plus Pred, some received Aza
54 Lai (1992) Transplanted from 1981 to 1991, at Chang Gung Memorial Hospital, Taipei Aza, Cs, or Aza plus Cs and Pred
55 Yap (2010) Transplanted from 1985 to 2008, at Queen Mary Hospital, Hong Kong Cs or Tac plus Pred; some received Mmf
HBsAg-seropositive population controls
56 Iloeje (2007) Community-based HBsAg-pos screening program
57 Chen (2006) Community-based follow-up
ALG, antilymphoblast globulin; ALcG, antilymphocyte globulin; Aza, azathioprine; Cs, cyclosporine; HBsAg, hepatitis B surface antigen; Mmf, mycophenolate mofetil; Pred,
prednisone, prednisolone, or methylprednisolone; Tac, tacrolimus.
a Personal correspondence (V. Lezaic, May 29, 2012).
b Personal correspondence (E. Ridruejo, August 31, 2010).
c Personal correspondence (E. Ridruejo June 11, 2012).
d Seems to be the same cohort as Huo et al., 2000 and Huo et al., 2001, except with more patient data collected.
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It is well known that the rates of HCC are much higher among
Asian compared to non-Asian populations for HBsAg-seropositive
persons of the general population.45,57 Therefore studies from high
seroprevalence areas were analyzed separately. The allocation of
studies to high seroprevalence (8%) areas versus low and
intermediate seroprevalence (<8%) of HBsAg was based on a
survey of World Health Organization (WHO) data.582.4. HBsAg-seropositive RT patients versus HBsAg-seropositive
persons of the general population
The overall rate of HCC among RT patients was calculated by
two different methods. Zero count data causes mathematical
problems for many meta-analytic techniques. Studies that report
zero counts in both arms of exposed/unexposed prospective
studies are frequently excluded from analysis. However, this may
result in exclusion of important studies. Another common
C.B. Blackadar / International Journal of Infectious Diseases 17 (2013) e24–e36 e27technique is to add a small number, such as 0.5 to studies that
report zero event counts. However, the use of continuity correction
factors has been demonstrated to introduce bias.59
Pooling the data, then analyzing multiple studies as one large
study, has been frequently criticized for analysis of paired studies
with normal distributions.60 However, a simulation analysis
reported that the pooling method yielded very little bias for
analysis of rare event data with frequent zero count cells.61 Pooling
the data of Table 2 permits the inclusion of all the studies withoutTable 2
Mortality rates for hepatocellular carcinoma (HCC), non-malignant liver disease (NMLD), 
seropositive persons of the general population
Ref. Lead author (year) Country Number of
patients
Mean
durationa
Person-
yearsb
Countries with low and intermediate rates of HBsAg seroprevalence
HBsAg-seropositive renal transplant recipients
22 Breitenfeldt (2002) Germany 37 9.2 340 
23 Correa (2003) Brazil 21 7.6 159 
24 Aroldi (2005) Italy 77 13.3 1026 
25 Lezaic (2008) Serbia 86 5.3 460 
26 Ridruejo (2010) Argentina 23 6.4 147 
27 Shons (1977) USA 35 4 140 
28 Sengar (1989) Canada 24 9.3 223 
29 Hiesse (1992) France 107 10.7 1141 
30 Berne (1977) USA 21 4.7 99 
31 Weir (1985) USA 20 12 240 
32 Norder (1989) Sweden 22h 9.3 206 
33 Parfrey (1985) Canada 22 6.9 152 
10 Fornairon (1996) France 151 10.4g 1573 
34 LeFrancois (1987) France 30 5.2 156 
35 Kliem (1994) Germany 69 10.1j 698 
36 Moreno (1990) Spain 11 5.0g 55 
37 Grekas (1995) Greece 14 4.5 63 
38 Friedlaender (1989) Israel 11 8.0 88 
39 Agarwal (2002) India 23 7.0 161 
40 Roy (1996) India 22 4.9 107 
41 Yagisawa (1997) Japan 18 6.5g 116 
42 Teo (2000) Malaysia 48 8.3 400 
43 Lawson (1988) Australia 16 9.1 146 
Subtotals/rates (pooled) 908 7896 
HBsAg-seropositive population controls
44 Ribes (2006) Spain 2206 20.6 45 444 
45 Crook (2003) Britain 3658 22.5 82 264 
Countries with high rates of HBsAg seroprevalence
HBsAg-seropositive renal transplant recipients
46 Dusheiko (1983) South Africa 18 8.9k 160 
47 Lee (2001) Taiwan 62 6.0 369 
50 Fan (2006) Taiwan 66 6.3 419 
51 Ahn (2007) South Korea 39 5.8 226 
52 Bang (1995) South Korea 79 4.1 326 
53 Sumethkul (2000) Thailand 19 5.4 103 
54 Lai (1992) Taiwan 61 4.1 250 
55 Yap (2010) Hong Kong 25 8.5 212 
Subtotals/rates (pooled) 369 2064 
HBsAg-seropositive population controls
56 Iloeje (2007) Taiwan 3931 12.5 49 138 
57 Chen (2006) China 2763 11 30 393 
Totals (HBsAg transplant) 1277 9960 
HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; NA, not available; 
a Duration of follow-up is expressed in years.
b Crude person-years of follow-up (number of patients multiplied by the mean dura
c Age at mid-point was estimated by adding the age at the beginning of follow-up a
d Deaths due to all causes including HCC and NMLD.
e The crude rate is given in parenthesis: number of patients who died due to all causes
100.
f NMLD, non-malignant liver disease; total deaths due to liver diseases minus the n
g Median period of follow-up or median age.
h Two patients were omitted because they were aged <10 years.
i Approximation based on the entire cohort of HBsAg-seropositive and seronegative 
j The mean graft survival of HBsAg-seropositive patients is stated to be 9.2 years. It was
about 10% longer than graft survival.
k Estimated from diagram in text.
l Average age was approximated by the formula
P
(agei person-yearsi)/
P
(person-ythe use of correction factors. Studies are weighted for their person-
years of follow-up. Studies that report zero HCC deaths contribute
person-years of follow-up to the total number of person-years,
which contributes to decreasing the overall rate of HCC. This is
referred to as the pooled method in the tables and ﬁgures.
A second method was employed, adapted from Baggaley
et al.62 They published an adaptation of the Wilson score
method for meta-analysis of binary data with zero count cells.
HCC mortality data has a Poisson distribution, so the method ofand from all causes among HBsAg-seropositive renal transplant patients and HBsAg-
Age at
mid-pointc
Sex, M/F Total deathsd,e Number
of NMLDe,f
Number
of HCCe
45.2 23/14 19 (5.6) 2 (0.6) 0 (0.0)
41.2 14/7 7 (4.4) 0 (0.0) 0 (0.0)
40.2 52/25 24 (2.3) 10 (1.0) 5 (0.5)
37.7 64/22 20 (4.4) 9 (2.0) 3 (0.7)
38.8 21/2 9 (6.1) 1 (0.7) 3 (2.0)
NA NA 9 (6.4) 1 (0.7) 0 (0.0)
45.7i NA 16 (7.2) 5 (2.2) 0 (0.0)
42.3 72/35 60 (5.3) 15 (1.3) 0 (0.0)
NA NA NA 0 (0.0) 0 (0.0)
NA NA 5 (2.1) 3 (1.3) 0 (0.0)
44.1 20/2 12 (5.8) 3 (1.5) 0 (0.0)
38.5 17/5 14 (9.2) 8 (5.2) 3 (2.0)
51.2g 116/35 41 (2.6) 11 (0.7) 4 (0.3)
32.5 23/7i NA 4 (0.9) 0 (0.0)
45.3 NA 26 (3.7) 18 (2.6) 1 (0.1)
NA NA 2 (3.6) 0 (0.0) 1 (1.8)
43.6 13/1 7 (11.1) 1 (1.6) 0 (0.0)
33.5 3/8 4 (4.5) 0 (0.0) 0 (0.0)
33.0i 20/3i NA 4 (2.5) 0 (0.0)
NA NA 3 (2.8) NA 0 (0.0)
37.9 12/6 5 (5.1) 4 (3.4) 0 (0.0)
34.6 33/15i 10 (2.5) 2 (0.5) 0 (0.0)
54.2 10/6 8 (5.5) 2 (1.4) 0 (0.0)
43.3l 518/188 (73% male) 301 (4.02) 103 (1.32) 20 (0.25)
43.8 (71% male) 211 (0.5) 40 (0.1) 15 (0.03)
40.2 (73% male) 420 (0.05) 52 (0.1) 21 (0.03)
NA 9/9 3 (1.9) 1 (0.6) 0 (0.0)
38.0 48/14 19 (5.1) 9 (2.4) 4 (1.1)
39.7 40/26 26 (6.2) 13 (3.1) 7 (1.7)
37.9 30/9 21 (9.3) 10 (4.4) 1 (0.4)
42.4 57/22 20 (6.5) 8 (2.6) 1 (0.3)
NA NA 6 (5.7) 2 (1.9) 2 (1.9)
34.4 43/18i NA NA 1 (0.4)
48.3 16/9 14 (6.6) 9 (4.3) 0 (0.0)
38.5l 243/107 (69% male) 109 (6.01) 52 (2.87) 16 (0.78)
52.6 (59% male) 425 (0.9) 41 (0.1) 138 (0.3)
47.4 (60% male) 447 (1.5) 85 (0.3) 231 (0.8)
410 155 36
NMLD, non-malignant liver disease.
tion of follow-up).
nd half the mean follow-up.
 (or NMLD or HCC), divided by the number of person-years follow-up multiplied by
umber of deaths due to HCC.
patients.
 estimated from the diagram of graft survival that the mean patient survival was only
earsi).
Populaon Control s fo r low and in termediate areas 
(44)  Rib es (Spain)
(45)  Crook  (Britain)
0.00033 (0.00018, 0.00054)
0.00026 (0.00016, 0.0 0039)
0.010 0.020 0.030 0.0400.000
Rate (H CC deaths/ per -yr)
HBsAg  sero-posive transplant paen ts in  are as of low 
and interme diate seroprev alence of HBsAg 
HBsAg  sero-posive transplant paen ts in  are as of
high  seroprevalence of HBsAg 
Populaon Control s fo r high  areas 
0.0028 (0.0024, 0.0033)
0.0076 (0.0067, 0.0087)
(56)  Iloej e (Tai wan)
(57 ) Chen (C hina)
0.010 0.020 0.030 0.0400.000
Rate (H CC deaths/ per -yr)
Overall rate (poo led)
Ref, autho r, countr y  
(35)  Kliem (H,  Germ.)
(33)  Parf.  (Mtl, Can.)
(28) Se ng. (O , Can.)
(10)  Forn.  (P, France)
(34)  LeFr. (L, France)
(22)  Breit.  (F,  Germ.)
(24)  Aroldi (Italy)
(37) Grekas  (Gree ce)
(25)  Lezaic (Serbia)
(38)  Frie dl.  (Israel)
(39) Agar wal  (Ind ia)
(41) Yagisa . (Japan)
(42) Teo  (Malaysia)
(30)  Ber ne (LA,  US A)
(29)  Hiesse (Fran ce)
(23)  Correa  (Brazil)
(27)  Shons (Mn, USA)
(26)  Ridrue (Argen)
(31)  Weir  (Bost, US A)
(32)  Norder  (Sweden)
(36) Mo reno (Spain)
(40)  Roy  (Ind ia)
(43)  Lawson  (Austral .)
0.0025 (0.0016, 0.0039 )
0.000 (0.000, 0.011)
0.005 (0.0016, 0.011)
0.007 (0.0014, 0.019)
0.000 (0.000, 0.0032)
0.000 (0.000, 0.038)
0.020 (0.0041, 0.058)
0.000 (0.000, 0.017)
0.003 (0.001, 0.0065)
0.000 (0.000, 0.024)
0.001 (0.0001, 0.0080)
0.000 (0.000, 0.057)
0.000 (0.000, 0.042)
0.000 (0.000, 0.023)
0.000 (0.000, 0.032)
0.000 (0.000, 0.025)
Rate (95% CI )  
0.000 (0.000, 0.023)
0.000 (0.000, 0.026)
0.000 (0.000, 0.015)
0.000 (0.000, 0.018)
0.020 (0.0042, 0.060)
0.018 (0.0001, 0.101)
0.000 (0.000, 0.035)
0.000 (0.000, 0.010)
Overall rate (P-IV) 0.0015 (0.000, 0.0035 )
(53) Su m. (Thailand)
(52)  Bang (S Korea)
(46)  Dush. (S Africa)
(54)  Lai (Tai wan)
(47)  Lee (Tai wan)
(50)  Fan (Tai wan)
(55) Yap ( H. Kong)
Overall rate (poo led)
(51) Ah n (S Korea)
Ref, autho r, countr y
Overall rate (P-IV)
0.000 (0.000, 0.023)
0.011 (0.0030, 0.028)
0.017 (0.0067, 0.034)
0.0044 (0.0001, 0.025)
0.0031 (0.0001, 0.017)
0.019 (0.0024, 0.070)
0.000 (0.000, 0.017)
0.0040 (0.0001, 0.022)
0.0078 (0.0044, 0.013)
Rate (95% CI )  
0.0060 (0.000, 0.013)
Figure 2. Mortality rates for HCC and 95% CI for HBsAg-seropositive renal transplant
patients versus HBsAg-seropositive persons of the general population from Table 2.
P-IV, Poisson inverse variance method. Dashed line centers on the overall rate, as
calculated by the pooled method.
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termed the Poisson inverse variance method, and this was
performed as follows. The conﬁdence intervals (CIs) of individual
studies were calculated using tabular data for Poisson events,63
along with the method described by Daly64 for converting the CIs
of events into CIs of rates. Formulas for the method follow.
wi ¼ 1=ðupper bound of the Poisson CIi=zÞ2 [1]
Overall u ¼ Sðwiui=SwiÞ [2]
SEa of overall u ¼ 1=
ﬃﬃﬃﬃ
S
p
wi [3]
95% CI of overall u ¼ overall u þ= zSEa [4]
where wi denotes the weight for study i, z = 1.96, the standard
normal deviate for the two-tailed probability of a = 5, ui denotes
the rate of study i, and SEa is an approximation of the standard
error. Equation [1] was derived from Baggaley et al.62, equations
[2–4] were derived from Deeks et al.65
Comparisons of the pooled rate (or Poisson inverse variance
overall rate) with each of the population trials were performed
using the method described by Kirkwood and Sterne for the
comparison of two Poisson rates.66,67
Each of the general population cohort studies followed over
1000 patients. Therefore, it was considered that differences in the
mortality rates of the different general population studies
represented differences among unique geographic populations,
rather than random sampling error due to small sample sizes. For
this reason the mortality rates of the general population studies
were not combined. It was reasoned that if the RT patients were
different from one population study, but not another, then the
differences were due to heterogeneity of unique geographic
populations, rather than the effect of immunosuppressive therapy
on the course of HBV infection. Signiﬁcant differences between
both population cohort studies should be considered to reﬂect
signiﬁcant treatment effects of immunosuppressive therapy on the
course of HBV infection.
2.5. HBsAg-seropositive RT patients versus HBsAg-seronegative RT
patients
Heterogeneity was quantiﬁed using the I2 test.68 For the
individual studies, the CIs of the relative rates (RRs) were
calculated by the likelihood scores method of Graham et al.69
using the software provided by Robert G. Newcombe’s website
at http://www.cardiff.ac.uk/medic/. The overall RRs and the CIs
of the overall RRs for ﬁxed effects were calculated by the
Mantel–Haenszel method as outlined by Deeks et al.65 The
formulas for the Mantel–Haenszel method were set up in
templates in Excel 2007, and tested using the examples provided
in the text65 and related literature.61 The overall RRs and CIs for
random effects analyses were calculated by the DerSimonian
and Laird method70 using MetaXL software, which was down-
loaded from http://epigear.com.
2.6. Analysis of dose–response to immunosuppressive therapy
A meta-regression analysis was performed for the mean dosage
of azathioprine and the rate of HCC. Meta-regression was also
performed for NMLD and all-cause mortality. The analysis was
repeated for the mean dosage of steroids versus HCC, NMLD, and
all-cause mortality. Fornairon et al.10 was excluded from regres-
sions of steroids. (It was considered an outlier because the dosages
were much higher than the other studies.) The software employed
for meta-regression was Comprehensive Meta-analysis.3. Results
3.1. Study selection
The included studies are summarized in Tables 1 and 2. In
addition to the exclusion criteria listed above, one study was
excluded because it was judged to be a case of plagiarism.71 The
data and text were almost identical to an included study.48 One
study reported 4 years of follow-up, but patients who survived less
than 2 years were not included.72 This reduced the actual follow-
up to 2 years. The studies that were included reported follow-up
for patients who survived for 1 month, 3 months, 12 months, etc.,
so this study was excluded. In one study hepatitis B e antigen
C.B. Blackadar / International Journal of Infectious Diseases 17 (2013) e24–e36 e29(HBeAg)-seropositive patients were treated with antivirals.73
HBeAg is considered a risk factor for HCC,74 so the study was
excluded.
Eight studies published after 2005 were identiﬁed for possible
inclusion. The responses to the e-mail queries concerning antiviral
treatment were as follows. One study replied that the patients
were not treated with antivirals, and was included.25 Five studies
indicated that their patients were treated with antivirals, and were
excluded. Two studies did not respond. The authors of Fan et al. did
not respond;50 it was decided to include their study because
antiviral therapy only became widely utilized in Taiwan in 2002
when a government funding program began, and their follow-up
ﬁnished in 2004. Authors of a second study from India published in
2009 did not reply; the study was excluded.
For two studies, it was difﬁcult to make an objective assessment
of whether any deaths from HCC occurred, so the studies were
excluded.75,76 In a supplementary analysis, these studies were
assumed to both have zero deaths from HCC. There was little effect
on the overall analysis (data not shown).
Two studies included in the analysis of Fabrizi et al.13 were
ineligible due to insufﬁcient follow-up.77,78 However, updates
were published that had sufﬁcient follow-up, so the updates were
included.26,55 A third study79 included by Fabrizi et al. was
excluded because it did not indicate HCC mortality, and no eligible
updates were identiﬁed.
3.2. RR of HCC for HBsAg-seropositive RT patients versus persons of
the general population
Studies that reported mortality for HCC among HBsAg-
seropositive RT patients are presented in Table 2. The mortality
rates for HCC among HBsAg-seropositive RT patients were
compared with mortality rates for HBsAg-seropositive persons
of the general population. The results are shown in Figure 2 and
Table 3.
The mortality rate of HCC was signiﬁcantly increased compared
to each of the population studies from low and intermediate
seroprevalence areas. Analysis by the pooled method yielded a RR
of 7.67 (95% CI 3.93–15.0) for HCC mortality compared to Ribes
et al.44 and 9.92 (95% CI 5.38–18.3) compared to Crook et al.45
Concerning high seroprevalence areas, the RR of HCC mortality was
signiﬁcantly increased compared to Iloeje et al.,56 2.76 (95% CITable 3
Analysis of HBsAg-seropositive renal transplant patients versus HBsAg-seropositive pe
Event, analysis Ratea
Countries with low and intermediate seroprevalence of HBsAg
Total liver diseases,b pooled method 1.56 
Total liver diseases,b Poisson inverse variance method 1.26 
NMLD, pooled method 1.32 
NMLD, Poisson inverse variance method 1.03 
HCC, pooled method 0.25 
HCC, Poisson inverse variance method 0.15 
Event, analysis Ratea
Countries with high seroprevalence of HBsAg
Total liver diseases,b pooled method 3.69 
Total liver diseases,b Poisson inverse variance method 3.33 
NMLD, pooled method 2.87 
NMLD, Poisson inverse variance method 2.62 
HCC, pooled method 0.78 
HCC, Poisson inverse variance method 0.60 
95% CI, 95% conﬁdence interval; HBsAg, hepatitis B surface antigen; HCC, hepatocellular c
a Rates were multiplied by 100.
b NMLD + HCC.1.64–4.63), but not increased compared to Chen et al.,57 1.02
(95% CI 0.61–1.69). The Poisson inverse variance method yielded
similar results (Table 3).
Ten studies from low and intermediate seroprevalence areas
stated the dosage of azathioprine dispensed. A meta-regression
analysis was performed for the HCC mortality rate versus the
dosage of azathioprine. However, the analysis was not informative
because only three of the 10 studies with dosage information
reported HCC deaths, while seven of the 10 studies reported no
deaths due to HCC. Fourteen studies from low and intermediate
seroprevalence areas indicated the steroid dosage administered,
and seven of these studies reported HCC deaths. Meta-regression
did not detect a correlation between the steroid dosage and HCC
mortality rates.
3.3. RR of NMLD for HBsAg-seropositive RT patients versus persons of
the general population
Studies that reported mortality for NMLD are listed in Table 2,
and the analysis is shown in Figure 3 and Table 3. Concerning low
and intermediate seroprevalence areas, the pooled method yielded
a RR of mortality from NMLD compared to Ribes et al.44 of 20.6
(95% CI 14.8–28.8) and compared to Crook et al.45 yielded a RR of
20.6 (95% CI 14.8–28.8). Concerning high seroprevalence areas, the
RR of NMLD mortality compared to Iloeje et al.56 was 34.4 (95% CI
22.8–51.7) and compared to Chen et al.57 was 10.3 (95% CI 7.26–
14.5). The Poisson inverse variance method produced similar
results (Table 3).
Meta-regression did not detect a correlation between the
dosage of immunosuppressive therapy (steroids or azathioprine)
and NMLD mortality.
3.4. RR of all-cause mortality for HBsAg-seropositive versus HBsAg-
seronegative RT patients
Studies that reported mortality for HBsAg-seropositive and
seronegative RT patients are listed in Table 4. The analysis is
presented in Figure 4 and Table 5. Eight studies from low and
intermediate seroprevalence areas met the inclusion criteria
and displayed minimal heterogeneity (I2 = 0%). The RR for low
and intermediate seroprevalence areas was analyzed by ﬁxed
effects: RR 2.12 (95% CI 1.77–2.54). Only four studies met thersons in the general population from Table 2
RT patients versus Ribes RT patients versus Crook
RR 95% CI RR 95% CI
12.9 9.37–17.7 17.6 13.1–23.5
10.4 7.55–14.3 14.1 10.6–18.9
14.8 10.3–21.4 20.6 14.8–28.8
11.7 8.13–16.9 16.3 11.7–22.8
7.67 3.93–15.0 9.92 5.38–18.3
4.49 2.30–8.77 5.81 3.15–10.7
RT patients versus Iloeje RT patients versus Chen
RR 95% CI RR 95% CI
10.1 7.66–13.4 3.55 2.73–4.62
9.15 6.92–12.1 3.21 2.47–4.17
34.4 22.8–51.7 10.3 7.26–14.5
31.5 20.9–47.4 9.39 6.65–13.3
2.76 1.64–4.63 1.02 0.61–1.69
2.14 1.28–3.60 0.79 0.48–1.31
arcinoma; NMLD, non-malignant liver disease; RR, relative rate; RT, renal transplant.
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Figure 3. Mortality rates for NMLD and 95% CI for HBsAg-seropositive renal
transplant patients and HBsAg-seropositive persons of the general population from
Table 2. P-IV, Poisson inverse variance method. Dashed line centers on the overall
rate, as calculated by the pooled method.
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Figure 4. Relative rates (RR) of mortality due to all causes and 95% CI for HBsAg-
seropositive renal transplant patients versus HBsAg-seronegative renal transplant
patients from Table 4.
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Figure 5. Meta-regression of the rate of all-cause mortality versus the dosage of
steroids by random effects unrestricted maximum likelihood method.
Slope = 0.0010, df = 17, I2 = 23.9%, p = 0.0814. Dashed circles, HBsAg-
seronegative renal transplant patients; solid circles, HBsAg-seropositive renal
transplant patients. The circle size reﬂects the weight of the study for the meta-
regression.
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a high level of heterogeneity (I2 = 87%). The RR for high
seroprevalence areas was analyzed by the random effects
method: RR 5.15 (95% CI 1.94–13.8). The RR of non-liver-related
deaths was also analyzed. The RR of non-liver-related deaths for
low and intermediate seroprevalence areas analyzed by ﬁxed
effects was 1.47 (95% CI 1.19–1.81, I2 = 31%) and for high
seroprevalence areas was analyzed by random effects and was
2.18 (95% CI 0.69–6.94, I2 = 77%).
Increases in mortality due to all causes among RT patients
compared to persons of the general population were expected, as a
reﬂection of their transplant status, regardless of their HBV status,
and were found to be so (data not shown).
Seven studies reported both azathioprine dosages and all-cause
mortality. Meta-regression of the seven studies did not detect acorrelation using the ﬁxed effects model or using the random
effects model.
Eleven studies reported both steroid dosage levels and all-
cause mortality. Meta-regression of the steroid dosage versus all-
cause mortality yielded a strongly signiﬁcant correlation using a
ﬁxed effects model, but was not signiﬁcant with the random
effects model. Meta-regression analysis was also performed for
the HBsAg-seronegative RT patients from low and intermediate
seroprevalence areas in Table 4. (Seven studies reported data
concerning steroid dosage and all-cause mortality.) Analysis of
this group also yielded a strongly signiﬁcant correlation employ-
ing the ﬁxed effects model, but the relationship was not
signiﬁcant using the random effects model. The HBsAg-seroposi-
tive and seronegative RT patients were then combined in order to
determine how the increased number of patients would inﬂuence
the analysis. Meta-regression again yielded a strongly signiﬁcant
correlation with the ﬁxed effects model, and a non-signiﬁcant
correlation using the random effects model. The plot for the
analysis of the combined group employing the random effects
model is shown in Figure 5.
Table 4
Mortality rates for hepatocellular carcinoma (HCC), non-malignant liver disease (NMLD), and from all causes among HBsAg-seropositive versus HBsAg-seronegative renal
transplant patients
Ref. Author Country HBsAg-seropositive renal transplant patients HBsAg-seronegative renal transplant patients
No. of
patients
Person-
yearsa
Total
deathsb,c
NMLDc HCCc No. of
patients
Person-
yearsa
Total
deathsb,c
NMLDc HCCc
Countries with low and intermediate seroprevalence of HBsAg
22 Breitenfeldt Germany 37 340 19 (5.6) 2 (0.6) 0 (0.0) 767 7056 150 (2.1) 2 (0.3) 0d (0.0)
23 Correa Brazil 21 159 7 (4.4) 0 (0.0) 0 (0.0) 52 383 10 (2.6) 0 (0.0) 0 (0.0)
24 Aroldi Italy 77 1026 24 (2.3) 10 (1.0) 5 (0.5) 255 3570 26 (0.7) 0 (0.0) 0 (0.0)
25 Lezaic Serbia 86 460 20 (4.4) 9 (2.0) 3 (0.7) 278 1645 46 (2.8) 2 (0.1) 1 (0.1)
26 Ridruejo Argentina 23 147 9 (6.1) 1 (0.7) 3 (2.0) 519 3322 85 (2.6) 2 (0.1) 2 (0.1)
27 Shons USA 35 140 9 (6.4) 1 (0.7) 0 (0.0) 35 140 8 (5.7) 0 (0.0) 0 (0.0)
28 Sengar Canada 24 223 16 (7.2) 5 (2.2) 0 (0.0) 157 1382 54 (3.9) 0 (0.0) 0 (0.0)
29 Hiesse France 107 1141 60 (5.3) 15 (1.3) 0 (0.0) 508 5436 128 (2.4) 6 (0.1) 0 (0.0)
Subtotal 410 3637 164 (4.5) 43 (1.2) 11 (0.3) 2571 22 935 507 (2.2) 12 (0.05) 3 (0.01)
Countries with high seroprevalence of HBsAg
47 Lee Taiwan 62 369 19 (5.1) 9 (2.4) 4 (1.1) 279 1590 30 (1.8) 3 (0.2) 4 (0.3)
48,49e Huo Taiwan 29 146 6 (4.3) 4 (3.4) 1 (0.6) 109 589 14 (2.4) 1 (0.2) 0 (0.0)
51 Ahn S Korea 39 226 21 (9.3) 10 (4.4) 1 (0.4) 1988 11 497 101 (0.9) 1 (0.01) 0 (0.0)
55 Yap H. Kong 25 212 14 (5.6) 9 (3.6) 0 (0.0) 63 843 3f (0.4) 0 (0.00) 0 (0.0)
Subtotal 155 990 60 (6.1) 32 (3.2) 6 (0.6) 2438 14 519 148 (1.0) 5 (0.03) 4 (0.03)
HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; NMLD, non-malignant liver disease.
a Crude person-years of follow-up (number of patients multiplied by mean (or median) duration of follow-up in years).
b Deaths due to all causes including HCC and NMLD.
c Crude rates are given in parenthesis: number of patients who died due to all causes (or NMLD or HCC), divided by the number of person-years follow-up multiplied by 100.
d Fourteen cases of cancer occurred among HBsAg-negative transplant recipients, but it was not indicated whether these included any cases of HCC. Since HCC is rare in this
region, it was assumed that no cases of HCC occurred.
e Data for HBsAg-seropositive patients were extracted from 48 and for HBsAg-seronegative patients were extracted from 49.
f Personal communication (T.M. Chan, July 16, 2010).
Table 5
Analysis of HBsAg-seropositive versus HBsAg-seronegative renal transplant patients from Table 4
Event No. of studies Analysis RR 95% CI I2 a
Countries with low and intermediate seroprevalence of HBsAg
Deaths due to all causes 8 Fixed 2.12 1.77–2.54 0%
Deaths due to all causes minus NMLD and HCC 8 Fixed 1.47 1.19–1.81 31%
Countries with high seroprevalence of HBsAg
Deaths due to all causes 4 Random 5.15 1.94–13.8 87%
Deaths due to all causes minus NMLD and HCC 4 Random 2.18 0.69–6.94 77%
95% CI, 95% conﬁdence interval; HBsAg, hepatitis B surface antigen; HCC, hepatocellular carcinoma; NMLD, non-malignant liver disease; RR, relative rate.
a I2 heterogeneity statistic (see Ref. 68).
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4.1. Publication bias
The focus of most of the studies included in this analysis was
simply to report mortality and include a brief description of each of
the causes of death. There appeared to be little bias to report HCC
mortality, though there were a few exceptions. Among the studies
that originated from low and intermediate seroprevalence areas,
Parfrey et al.33 and Fornairon et al.10 prominently reported HCC
mortality in the title and/or the abstract. The appearance of the
term HCC in the title and/or abstract was considered indicative that
the cases may have inﬂuenced the decision to publish. From high
seroprevalence areas, only Fan et al.50 highlighted their cases of
HCC mortality. Two additional studies were found that highlighted
the cases of mortality from HCC.80,81 They were excluded because
they did not indicate the number of persons who were HBsAg-
seropositive and did not develop HCC. Efforts to correspond with
the authors were unsuccessful.
4.2. Author bias
Initially it was assumed that the rate of HCC was increased, and
a search was commenced to ﬁnd an appropriate reference(s) tounequivocally demonstrate this. The author was unable to ﬁnd a
convincing reference. The search extended so long and became so
thorough that it was decided to extend the search to develop a
systematic review/meta-analysis. Inclusion criteria for follow-up
were initially decided to be a minimum of 5 years and the
minimum number of patients to be 20. However, the assembled
data did not provide overwhelming support for the assumption
that the rate was increased. Shorter studies with few patients
seldom reported HCC mortality. Subsequently, it was decided to
include studies with only 4 years of follow-up and 10 patients in
order to test whether it could be deﬁnitively shown that the rate
was not increased. Analysis with the additional studies had little
impact overall, so the additional studies were included in this
analysis. The author welcomes correspondence from authors with
unpublished studies, authors who are willing to supply required
data for studies that were excluded, and notiﬁcation of any eligible
studies that might have been missed in the search. If sufﬁcient
additional data are received, the author will consider publishing a
brief reanalysis of the data.
Multiple authors working together does not necessarily prevent
bias. Junior authors may not feel comfortable presenting/insisting
on dissenting opinions. Furthermore, bias may be present in an
entire collaboration. The best method to correct for bias is for
different authors to investigate the same subject using indepen-
C.B. Blackadar / International Journal of Infectious Diseases 17 (2013) e24–e36e32dently derived search/inclusion criteria and to publish their
results.
4.3. HCC in low and intermediate seroprevalence areas
The small number of studies that reported HCC deaths from low
and intermediate seroprevalence areas is a limitation of this
analysis (Table 2). A few outlier studies that report a few cases of a
rare event combined with many studies that report zero events can
generate misleading results. A number of center-speciﬁc factors
could have contributed to the fact that a few studies reported
clusters of HCC deaths from low and intermediate seroprevalence
areas.
Differences in the proportions of migrants from high seroprev-
alence areas, where HBV infection occurs in early childhood and
the rates of HCC are high, could contribute to clusters of HCC
mortality.
Different genotypes and subtypes affect the rates of HCC
mortality in the general population.82 Infections acquired during
dialysis and transplantation could result from a restricted number
of common ‘donor’ cases of HBV infection from a few cases in the
same center. This would result in a narrower spectrum of
genotypes, subtypes, and variants at transplant centers than
occurs in the normal population. Infection with a common
carcinogenic genotype/subtype/variant at some centers could
contribute to high rates of HCC mortality at those centers.
High levels of alcohol consumption among RT patients have
been remarked on in various studies.28,83–85 Cultural differences
between centers could inﬂuence alcohol consumption and increase
the carcinogenic potential of HBV.
Iron overload could possibly account for some differences in the
rates of HCC mortality. Anemia is common among dialysis and RT
patients due to a variety of causes.86 The amount of iron used to
prevent/treat anemia in dialysis and RT patients has traditionally
varied considerably between different centers. Aggressive treat-
ment with iron has resulted in iron overload in many dialysis
patients87 and some RT patients.88,89 Patients with the hereditary
iron storage disease known as hemochromatosis are characterized
with high rates of HCC mortality,90,91which demonstrates that iron
overload can cause liver cancer. Iron overload due to center-
speciﬁc differences in treatment protocols for anemia could
possibly result in an iron–HBV interaction, which could contribute
to the differences in rates of HCC mortality between centers.
Parfrey et al.33 and Aroldi et al.24 both attributed their HCC
deaths to the long duration of their studies. Regression analysis
showed that person-years of follow-up correlated more strongly
with HCC mortality than duration of follow-up (data not shown).
Three of four studies that reported over 500 person-years of
follow-up, reported at least one HCC death (Table 2). It seems likely
that inadequate person-years of follow-up accounts for the
observation that few studies reported HCC deaths. Each study
that reported one or more HCC deaths had a higher rate of HCC
mortality than each of the population cohorts. A pooled analysis of
the four studies with over 500 person-years of follow-up yielded a
rate of 0.23/100 person-years with a total of 4438 person-years of
follow-up. Analysis by the Poisson inverse variance method
yielded a rate of 0.15/100 person-years of follow-up. These rates
are very close to the rates calculated for all the studies of the low
and intermediate seroprevalence areas (compare Table 3).
Hoffmann et al.92 published an interesting analysis of the
incidence rate of HCC among recipients of various types of
transplants performed in the USA. Only four cases of HCC occurred
among 2240 HBsAg-seropositive non-liver transplant recipients
who were followed for a median of 2.9 years, for an incidence rate of
0.063/100 person-years. The study was excluded because the
follow-up was not long enough and mortality was not reported. Ithas been estimated that 50% of patients diagnosed with HCC die
within 9 months.93 If the study of Hoffmann et al. is extrapolated
for an additional 9 months, and two of the four cases of HCC are
estimated to have died, then the mortality rate would be 0.024/100
person-years. This is quite similar to the mortality rates of 0.03/100
person-years and 0.04/100 person-years for HBsAg-seropositive
persons among the general population of low and intermediate
seroprevalence areas presented in Table 2. The use of antiviral
therapy was likely widespread in this group, and could contribute
to the low rate of HCC. However, there are numerous reports that
HCC still occurs among antiviral-treated transplant recipi-
ents.51,55,94,95 It is relevant to mention that a large study conducted
by Pfaff and Blanton96 reported only a 4.2% reduction in survival of
HBsAg-seropositive RT patients. Their study was from the same
geographic area of the USA as the study by Hoffmann et al., and is
discussed further below in the section concerning mortality due to
all causes. It would be useful to review data concerning this cohort
after additional follow-up.
Perhaps the most important factor inﬂuencing the rate of HCC
mortality among HBsAg-seropositive RT patients was the level of
liver disease among patients prior to transplantation. Different
centers permitted different levels of disease among HBsAg-
seropositive persons accepted for transplantation.49,51,97 Centers
in the USA may have selected patients with lower levels of liver
disease.
4.4. HCC in high seroprevalence areas
Two factors likely contributed to an underestimation of the RR
of HCC mortality among the RT cohorts compared to the
population studies of high seroprevalence areas of Table 3. Older
age and male sex are both known to be associated with higher rates
of HCC mortality. However, the average age at the mid-point of the
RT studies was around a decade younger than in the population
cohorts (Table 2). Iloeje et al.56 calculated that the hazard ratio for
mortality due to HCC was 1.1 (95% CI 1.08–1.12) for each single
year increase in age after adjustment for various factors. This
would contribute to an underestimate of the RR of the RT cohorts
compared to the population cohorts.
There were also differences in the proportion of males between
the RT patients and the general population cohorts for areas of high
seroprevalence of HBsAg. Seventy percent of HBsAg-seropositive
RT patients were male, whereas 60% of the persons in the general
population cohorts were male. Male sex was associated with a
threefold increase in the crude rate and crude hazard ratio for
males in Asian population studies,98,99 though it was decreased to
around twofold after adjustment for various factors.56,98,99 The
lower proportion of males in the RT studies would also contribute
to a lower estimate of the RR of HCC mortality among RT patients.
The rate of HCC mortality was increased compared to the cohort
of Iloeje et al.56 from Taiwan, but not increased compared to the
cohort of Chen et al.57 of mainland China. The level of health
care has been generally lower in mainland China, which may have
contributed to their higher rates of NMLD and HCC.
Different surveillance practices may also contribute to differ-
ences in the number of HCC deaths in various studies.
4.5. Role of different immunosuppressive therapy regimens
Cyclosporine was introduced as an immunosuppressant in the
mid 1980s, and soon afterwards studies started reporting that the
rates of cancer were higher among patients receiving cyclospor-
ine.100–102 Most studies included in this analysis employed
azathioprine-based immunosuppressive regimens. Twelve of the
23 studies from low and intermediate seroprevalence areas
dispensed azathioprine-based therapies, whereas only two
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(Table 1). (Three studies did not state their regimen, and six
indicated that they employed a variety of therapies.) The cohort of
Lezaic et al.25 used a cyclosporine-based regimen and reported one
of the higher rates of HCC (0.7/100 person-years). The cohort of Roy
et al.40 also received cyclosporine-based therapy and had no HCC
deaths. A similar pattern was evident in high seroprevalence areas.
Only three studies used calcineurin-based therapy. The cohort of
Sumethkul et al.53 had the highest rate (1.9/100 person-years),
while Bang et al.52 had a rate among the lowest (0.3/100 person-
years) for high seroprevalence areas.
Dantal et al.103 compared the cancer rate of RT patients on two
different dosages of cyclosporine and found that patients who
received the higher dosage of cyclosporine had higher rates of
cancer. They concluded that the level of immunosuppression was
more important than the type of immunosuppressant. Steroids
have been shown to increase the activity of HBV in in vitro
studies,104 so it seemed relevant to perform a meta-regression of
the steroid dosage versus the rate of HCC. However, neither the
dosage of azathioprine nor the dosage of steroids was found to
correlate with the rate of HCC. There were few studies that
provided both the dosages of immunosuppressive therapy and had
HCC deaths. Only a very potent carcinogen would be expected to
evidence a correlation in a data set with few studies reporting HCC
deaths. This analysis had only a very weak ability to detect a dose–
response relationship between immunosuppressive dosage and
the rate of HCC.
4.6. Role of inﬂammation, viral load
HCC due to HBV infection usually develops through a
progression of hepatitis, to ﬁbrosis, to cirrhosis, then ﬁnally
HCC. Cirrhosis is considered to be caused by many years of
inﬂammation of hepatic tissue. Cirrhosis is also regarded as the
strongest known risk factor for HCC among HBsAg-seropositive
persons,99,105 so inﬂammation is widely considered to have an
important role in HCC.106,107 RT patients have strongly suppressed
T-lymphocyte activity and effectively reduced inﬂammatory
responses, which would be expected to reduce their rates of
HCC. However, inﬂammation is not completely inactivated in RT
patients, and cirrhosis is well documented to develop in HBsAg-
seropositive RT patients.10,33,50,95,108,109
Serum HBV DNA levels have recently become recognized as
having very strong associations with mortality due to NMLD and
HCC for in persons of the general population.99 Serum HBV
DNA levels are high in RT patients,95,110,111 due to their reduced
T-lymphocyte activity. Increased viral levels could possibly
compensate for a reduced role of inﬂammation in HBsAg-
seropositive RT patients.
4.7. NMLD
The RRs of NMLD were increased more consistently and
strikingly than the RRs of HCC (Tables 2 and 3, Figure 3). It is
noteworthy that only one of 30 RT studies yielded a rate of HCC
that was higher than the rate of NMLD, whereas the population
studies are heterogeneous, with some reporting higher rates of
HCC and others reporting higher rates of NMLD (Table 2). Liver
failure can be classiﬁed into three general categories: acute
liver failure (or fulminant hepatic failure), acute-on-chronic
liver failure, and chronic liver failure without a precipitating
event.112 Most authors of the studies included in this analysis
simply used the term ‘liver failure’ without further description.
Some authors provided more speciﬁc descriptions. They used
terms such as ‘fulminant hepatic failure’, ‘chronic liver failure’,
‘chronic liver disease’, and ‘cirrhosis’. It was evident fromthe reports that liver failure among RT patients took an
acute course in some patients and a chronic course in other
patients.
There is a paucity of literature concerning the mechanism of
liver failure among HBsAg-seropositive RT patients. Two studies
reported an absence of an immune response in biopsies of RT
patients with acute liver failure.113,114 Two other studies reported
that mononuclear cell inﬁltrates were predominant.115,116
4.8. Mortality due to all causes
This analysis conﬁrms the ﬁndings of Fabrizi et al.13 that the
relative risk of mortality due to all causes is signiﬁcantly increased
among HBsAg-seropositive RT patients compared to non-infected
patients. They reported an adjusted relative risk of 2.49 (95% CI
1.64–3.78) for mortality due to all causes using a random effects
model. Their analysis included a total of 336 seropositive RT
patients from four studies of Europe and South America plus two
studies from Asia. The present analysis included 410 HBsAg-
seropositive RT patients from eight studies of low and intermediate
seroprevalence areas, and yielded a RR of 2.12 (95% CI 1.77–2.54)
using a ﬁxed effect model. Analysis of an additional 155 HBsAg-
seropositive RT patients from four studies of high seroprevalence
areas yielded a RR of 5.15 (95% CI 1.94–13.8) using a random effects
model.
Some studies reported only marginal, or no difference in
survival of HBsAg-seropositive RT patients and did not meet the
inclusion criteria for this analysis. Pfaff and Blanton conducted a
study of 781 HBsAg-seropositive RT patients from multiple centers
in the south-eastern USA.96 Pfaff and Blanton reported that
survival was signiﬁcantly reduced by 4.2% in HBsAg-seropositive
patients after 10 years of follow-up. This represented only a 1.1-
fold increase in mortality. A smaller study would have found that
the difference was not signiﬁcant. A 10-year actuarial study of 25
HBsAg-seropositive RT patients from Florida reported no effect on
overall survival.117 A 10-year actuarial study from Mexico also
reported no difference in survival.118 A 10-year actuarial study of
155 HBsAg-seropositive RT patients from Lyon, France, similarly
reported no difference in survival.119 Fornairon et al.10 reported an
actuarial follow-up of 151 HBsAg-seropositive RT patients at the
Necker Hospital of Paris, and reported no difference in survival
compared to 1247 seronegative patients after a median follow-up
of 10.4 years. The same center has recently reported 30 years of
follow-up, and continues to report no difference in mortality.15 In
contrast, Hiesse et al.29 reported a twofold increase in mortality
among 107 seropositive patients at the Biceˆtre Hospital of Paris,
when compared to 507 seronegative patients after a mean follow-
up of 10.7 years. These two contrasting cohorts both from Paris,
France, suggest that there are center-speciﬁc factors affecting
survival. Hiesse et al.29 was included in the present analysis,
however the other studies were excluded because they did not
meet the inclusion criteria.
A recent study of patients transplanted from 2001 to 2007 in the
USA reported only a non-signiﬁcant 0.3% decrease in the 5-year
patient survival.120 This is equivalent to only a 1.02-fold increase in
mortality, and reﬂects further improvements in patient care in the
USA, including the widespread usage of nucleos(t)ide antivirals
since the late 1990s. Some large studies reported that survival
decreased only after 10 years of follow-up.29,35
Center-speciﬁc factors, which are discussed in the above section
concerning the mortality rate of HCC, may have similarly
contributed to differences in mortality due to NMLD and all
causes. Centers in the USA may have restricted acceptance of
patients for transplantation to those with minimal evidence of liver
disease, accounting for the favourable mortality rates reported by
studies from the USA. Hiesse et al.29 reported that they accepted
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their higher mortality rates.
This analysis found that high seroprevalence areas have a
higher RR of all-cause mortality, 5.15 (95% CI 1.94–13.8), compared
to low and intermediate seroprevalence areas, 2.12 (95% CI 1.77–
2.54) (Table 5). Persons from high seroprevalence areas are usually
infected during early childhood and would be expected to have
higher background rates of liver disease. This could have
contributed to the increased RR of all-cause mortality.
5. Conclusions
The analysis of the rates of HCC among HBsAg-seropositive RT
patients versus HBsAg-seropositive persons of the general
population is consistent with the rate of HCC being increased by
immunosuppressive therapy in low and intermediate seropreva-
lence areas. HCC is a rare event in low and intermediate
seroprevalence areas and most studies reported no deaths from
HCC. The pooled mortality rate of HCC for RT patients was
signiﬁcantly higher than the mortality rate of each of the
population cohorts. In high seroprevalence areas, HCC is a
relatively common event, and most studies reported deaths due
to HCC. The overall mortality rate of HCC was higher than one
population cohort, but not the other cohort. However the average
age of the RT patients was much younger and would have
contributed to a lower mortality rate of HCC among RT patients. It
is concluded that the overall evidence shows an increased RR of
mortality from HCC in low and intermediate seroprevalence areas
but was not conclusive for high seroprevalence areas.
NMLD is a much more frequent cause of death among HBsAg-
seropositive RT patients compared to HCC, and was clearly
increased in these RT patients compared to persons of the general
population in every analysis.
Most of the included studies from low and intermediate
seroprevalence areas reported that the RR of mortality due to all
causes was increased around twofold among HBsAg-seropositive
RT patients, however some large excluded studies reported
minimal or no increase. One very large excluded study from the
USA reported only a slight increase, and a few other large studies
that did not meet the inclusion criteria reported no increase, so
center-speciﬁc factors seem to have an important role. The
increase in mortality was quite pronounced in high seroprevalence
areas, though the studies were rather heterogeneous.
Acknowledgements
I want to thank Professor Arthur Hill of the Department of Food
Science, University of Guelph, for sponsoring my library privileges
at the University of Guelph. No ﬁnancial support was received to
write this review.
Conﬂict of interest: I have no conﬂicts of interest to disclose.
References
1. Hoshida Y, Aozasa K. Malignancies in organ transplant recipients. Pathol Int
2004;54:649–58.
2. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after organ
transplantation. Int J Cancer 2009;125:1747–54.
3. International Agency for Research on Cancer. Hepatitis viruses. Volume 59. 2.
Studies of cancer in humans. Lyon, France: IARC; 1994. p. 66–97.
4. Adami J, Babel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk
following organ transplantation: a nationwide cohort study in Sweden. Br J
Cancer 2003;89:1221–7.
5. Vajdic CM, McDonald SP, McCredie MRE, van Leeuwen MT, Stewart JH, Law M,
et al. Cancer incidence before and after kidney transplantation. JAMA
2006;296:2823–31.
6. Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer
incidence among Canadian transplant recipients. Am J Transplant 2007;7:
941–8.7. Li WS, Chen YJ, Tseng WC, Lin MW, Chen TJ, Chu SY, et al. Malignancies after
transplantation in Taiwan: a nationwide population-based study. Nephrol Dial
Transplant 2012;27:833–9.
8. Chen CH, Su WW, Yang SS, Chang TT, Cheng KS, Lin HH, et al. Long-term trends
and geographic variations in the survival of patients with hepatocellular
carcinoma: analysis of 11 312 patients in Taiwan. J Gastroenterol Hepatol
2006;21:1561–6.
9. Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H, Sobue T, et al., Research
Group of Population-Based cancer Registries of Japan. Population-based survival
of cancer patients diagnosed between 1993 and 1999 in Japan: a chronological
and international comparative study. Jpn J Clin Oncol 2011;41:40–51.
10. Fornairon S, Pol S, Legendre C, Carnot F, Mamzer-Bruneel MF, Brechot C, Kreis
H. The long-term virologic and pathologic impact of renal transplantation on
chronic hepatitis B virus infection. Transplantation 1996;62:297–9.
11. Davis CL, Gretch DR, Carithers Jr RL. Hepatitis B and transplantation. Infect Dis
Clin North Am 1995;9:925–41.
12. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, et al. Impact of
hepatitis B and C virus on kidney transplant outcome. Hepatology 1999;29:
257–63.
13. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and
survival after renal transplantation: meta-analysis of observational studies.
Am J Transplant 2005;5:2913–21.
14. Vallet-Pichard A, Fontaine H, Mallet V, Pol S. Viral hepatitis in solid organ
transplantation other than liver. J Hepatol 2011;55:74–82.
15. Bererhi L, Pallet N, Zuber J, Anglicheau D, Kreis H, Legendre C, Candon S.
Clinical and immunological features of very long-term survivors with a single
renal transplant. Transpl Int 2012;25:545–54.
16. Chan MK, Fernando ON, Moorhead JF. Hepatic malignancy after renal trans-
plantation in an HBsAg positive patient. Br J Clin Pract 1980;34:294–5.
17. Schroter GP, Weil 3rd R, Penn I, Speers WC, Waddell WR. Hepatocellular
carcinoma associated with chronic hepatitis B virus infection after kidney
transplantation. Lancet 1982;320:381–2.
18. Min SK, Huh S, Ahn MS, Jung IM, Ha J, Ahn C, et al. Malignancy in renal
transplant recipients. Transplant Proc 2000;32:1980–1.
19. Vegso G, Toth M, Hidvegi M, Toronyi E, Langer RM, Dinya E, et al. Malignancies
after renal transplantation during 33 years at a single center. Pathol Oncol Res
2007;13:63–9.
20. Arichi N, Kishikawa H, Nishimura K, Mitsui Y, Namba Y, Tokugawa S, Ichikawa
Y. Malignancy following kidney transplantation. Transplant Proc 2008;40:
2400–2.
21. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B:
special emphasis on disease progression and prognostic factors. J Hepatol
2008;48:335–52.
22. Breitenfeldt MK, Rasenack J, Berthold H, Olschewski M, Schroff J, Strey C, Grotz
WH. Impact of hepatitis B and C on graft loss and mortality of patients after
kidney transplantation. Clin Transplant 2002;16:130–6.
23. Correa JR, Rocha FD, Peres AA, Goncalves LF, Manfro RC. Efeito a longo prazo da
infeccao pelos virus das hepatites B e C na sobrevida de pacientes transplan-
tados renais. Rev Assoc Med Bras 2003;49:389–94.
24. Aroldi A, Lampertico P, Montagnino G, Montagnino G, Passerini P, Villa M, et al.
Natural history of hepatitis B and C in renal allograft recipients. Transplanta-
tion 2005;79:1132–6.
25. Lezaic V, Stosovic M, Marinkovic J, Rangelov V, Djukanovic L. Hepatitis B and
hepatitis C virus infection and outcome of hemodialysis and kidney transplant
patients. Renal Failure 2008;30:81–7.
26. Ridruejo E, Diaz C, Michel MD, Pujol GS, Martinez A, Marciano S, et al. Short and
long term outcome of kidney transplanted patients with chronic viral hepatitis
B and C. Ann Hepatol 2010;9:271–7.
27. Shons AR, Simmons RL, Kjellstrand CM, Najarian JS. Letter to the. N Engl J Med
1977;296:1169–70.
28. Sengar DP, Couture RA, Lazarovits AI, Jindal SL. Long-term patient and renal
graft survival in HBsAg infection: an update. Transplant Proc 1989;21:3358–9.
29. Hiesse C, Buffet C, Neyrat N, Rieu P, Charpentier B, Etienne JP, Fries D. Impact of
HBs antigenemia on long-term patient survival and cause of death after renal
transplantation. Clin Transplant 1992;46:461–7.
30. Berne TV, Fitzgibbons TJ, Silberman H. The effect of hepatitis B antigenemia on
long-term success and hepatic disease in renal transplant recipients. Trans-
plantation 1977;24:412–5.
31. Weir MR, Kirkman RL, Strom TB. The long-term effects of hepatitis B virus in
renal transplant recipients: analysis of morbidity and mortality. Transplanta-
tion Proc 1985;17:163–4.
32. Norder H, Brattstrom C, Magnius L. High frequency of hepatitis B virus DNA in
anti-HBe positive sera on longitudinal follow-up of patients with renal trans-
plants and chronic hepatitis B. J Med Virol 1989;27:322–8.
33. Parfrey PS, Forbes RD, Hutchinson TA, Kenick S, Farge D, Dauphinee WD, et al.
The impact of renal transplantation on the course of hepatitis B liver disease.
Transplantation 1985;39:610–5.
34. LeFrancois N, Elmghabbar N, Chossegros P, Betuel H, Faure JL, Revillard JP, et al.
Long-term results in kidney transplantation: patient and graft survival, causes
of graft failure and mortality, renal function and complications after 10 years.
Transplant Proc 1987;19:3767–8.
35. Kliem V, Ringe B, Holhorst K, Frei U. Kidney transplantation in hepatitis B
surface antigen carriers. Clin Investig 1994;72:1000–6.
36. Moreno F, Morales JM, Colina F, Prieto C, Andres A, Alcazar JM, et al. Inﬂuence
of long-term cyclosporine therapy on chronic liver disease after renal trans-
plantation. Transplant Proc 1990;22:2314–6.
C.B. Blackadar / International Journal of Infectious Diseases 17 (2013) e24–e36 e3537. Grekas D, Dioudis C, Mandraveli K, Alivanis P, Alexiou S, Derveniotis V, et al.
Renal transplantation in asymptomatic carriers of hepatitis B surface antigen.
Nephron 1995;69:267–72.
38. Friedlaender MM, Kaspa RT, Rubinger D, Silver J, Popovtzer MM. Renal
transplantation is not contraindicated in asymptomatic carriers of hepatitis
B surface antigen. Am J Kidney Dis 1989;14:204–10.
39. Agarwal SK, Dash SC, Mehta SN, Gupta S, Bhowmik D, Tiwari SC, Guleria S.
Results of renal transplantation on conventional immunosuppression in sec-
ond decade in India: a single centre experience. J Assoc Physicians India
2002;50:532–6.
40. Roy D, Ramakrishna B, Ramakrishna BS, Jacob CK, Shastry JC. Hepatitis B virus
(HBv) associated chronic liver disease in cyclosporine-treated renal allograft
recipients. Kidney Int 1996;50:1396.
41. Yagisawa T, Toma H, Tanabe K, Ishikawa N, Tokumoto N, Iguchi Y, et al. Long-
term outcome of renal transplantation in hepatitis B surface antigen-positive
patients in cyclosporine era. Am J Nephrol 1997;17:440–4.
42. Teo SM, Morad Z. Long-term effects of hepatitis B and C infection in renal
transplantation. Transplant Proc 2000;32:1950–1.
43. Lawson MJ, Fock KM, Gowans EJ, Mathew TH, Burrell CJ. Hepatitis B in renal
transplant recipients: an assessment of the relationship of viral replication to
liver pathology. J Gastroenterol Hepatol 1988;3:47–53.
44. Ribes J, Cleries R, Rubio A, Hernandez JM, Mazzara R, Madoz P, et al. Cofactors
associated with liver disease mortality in an HBsAg-positive Mediterranean
cohort: 20 years of follow-up. Int J Cancer 2006;119:687–94.
45. Crook PD, Jones ME, Hall AJ. Mortality of hepatitis B surface antigen-positive
blood donors in England and Wales. Int J Epidemiol 2003;32:118–24.
46. Dusheiko G, Song E, Bowyer S, Whitcutt M, Maier G, Meyers A, Kew MC.
Natural history of hepatitis B virus infection in renal transplant recipients: a
ﬁfteen-year follow-up. Hepatology 1983;3:330–6.
47. Lee WC, Shu KS, Cheng CH, Wu MJ, Chen CH, Lian JD. Long-term impact of
hepatitis B, C virus infection on renal transplantation. Am J Nephrol
2001;21:300–6.
48. Huo TI, Yang WC, Wu JC, King KL, Loong CC, Lin CY, et al. Impact of hepatitis B
and C virus infection on the outcome of kidney transplantation in Chinese
patients. Zhonghua Yi Xue Za Zhi (Taipei) 2000;63:93–100.
49. Huo TI, Yang WC, Wu JC, King KL, Loong CC, Lin CY, et al. Kidney transplanta-
tion in patients with chronic hepatitis B virus infection: is the prognosis
worse? Dig Dis Sci 2001;46:469–75.
50. Fan WC, King KL, Loong CC, Wu CL. Hepatocellular carcinoma after renal
transplantation: the long-term impact of cirrhosis on chronic hepatitis B virus
infection. Transplant Proc 2006;38:2080–3.
51. Ahn HJ, Kim MS, Kim YS, Kim SI, Huh KH, Ju MK, et al. Clinical outcome of renal
transplantation in patients with positive pre-transplant hepatitis B surface
antigen. J Med Virol 2007;79:1655–63.
52. Bang BK, Yang CW, Yoon SA, Kim YS, Chang YS, Yoon YS, Koh YB. Prevalence
and clinical course of hepatitis B and C liver disease in ciclosporin-treated
renal allograft recipients. Nephron 1995;70:397–401.
53. Sumethkul V, Jirakranont B, Jirasiritham S, Pairoj W. Eleven-year experience of
kidney transplantation in patients with hepatitis B and C infection. Transplant
Proc 2000;32:1944–5.
54. Lai MK, Huang CC, Chu SH, Chuang CK, Huang JY. Two hundred and thirty cases
of kidney transplantation: single-center experience in Taiwan. Transplant Proc
1992;24:1452–4.
55. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Long-term outcome of
renal transplant recipients with chronic hepatitis B infection—impact of
antiviral treatments. Transplantation 2010;90:325–30.
56. Iloeje UH, Yang H, Jen CL, Su J, Wang LY, You SL, et al. Risk and predictors of
mortality associated with chronic hepatitis B infection. Clin Gastroenterol
Hepatol 2007;5:921–31.
57. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past viral load as
predictor of mortality and morbidity from HCC and chronic liver disease in a
prospective study. Am J Gastroenterol 2006;101:1797–803.
58. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best
Pract Res Clin Gastroenterol 2008;22:991–1008.
59. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and
avoidance of continuity corrections in meta-analysis of sparse data. Stat
Med 2004;23:1351–75.
60. Baker SG, Kramer BS. Good for women, good for men, bad for people:
Simpson’s paradox and the importance of sex-speciﬁc analysis in observa-
tional studies. J Womens Health Gend Based Med 2001;10:867–72.
61. Bradburn MJ, Deeks JJ, Berlin JA, Localio AR. Much ado about nothing: a
comparison of the performance of meta-analytical methods in rare events.
Stat Med 2007;26:53–77.
62. Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for
parenteral exposure and blood transfusion: a systematic review and meta-
analysis. AIDS 2006;20:805–12.
63. Gardner MJ. Tables for the calculation of conﬁdence intervals. Table 18. 3. In:
Altman DG, Machin D, Bryant TN, Gardner MJ, editors. Statistics with conﬁ-
dence: conﬁdence intervals and statistical guidelines. 2nd ed., Bristol, UK: BMJ
Books; 2000. p. 219–21.
64. Daly LE. Conﬁdence limits made easy: interval estimation using the substitu-
tion method. Am J Epidemiol 1998;147:783–90.
65. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining hetero-
geneity and combining results from several studies in meta-analysis. In: Egger
M, Smith GD, Altman DG, editors. Systematic reviews in health care. 2nd ed.,
London: BMJ Publishing Group; 2001. p. 285–312.66. Kirkwood BR, Sterne JA. Chapter 22. Longitudinal studies, rates and the Poisson
distribution. In: editors. Essential medical statistics. 2nd ed. Malden, MS:
Blackwell Science; 2003, p. 227–39.
67. Kirkwood BR, Sterne JA. Chapter 23. Comparing rates. In: Essential medical
statistics. 2nd ed. Malden, MS: Blackwell Science; 2003, p. 240–8.
68. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in
meta-analyses. BMJ 2003;327:557–60.
69. Graham PL, Mengersen K, Morton AP. Conﬁdence limits for the ratio of two
rates based on likelihood scores: non-iterative method. Stat Med 2003;22:
2071–83.
70. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials
1986;7:177–88.
71. Lee SD. Plagiarism in scientiﬁc writing. J Chin Med Assoc 2008;71:273–4.
72. Sandrini S, Callea F, Cristinelli L, Savoldi S, Setti G, Scaini P, et al. Viral hepatitis
in HBsAg-positive renal transplant patients treated with cyclosporine and
steroids. Nephrol Dial Transplant 1990;5:525–30.
73. dos Santos CU, Seva-Pereira T, Alves-Filho G, Lorena SL, Mazzali M. Changes in
serological markers of hepatitis B virus after renal transplantation. Transplant
Proc 2008;40:749–51.
74. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, et al. Hepatitis B e antigen
and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168–74.
75. Fairley CK, Mijch A, Gust ID, Nichilson S, Dimitrakakis M, Lucas CR. The
increased risk of fatal liver disease in renal transplant patients who are
hepatitis B e antigen and/or HBV positive. Transplantation 1991;52:497–500.
76. Matos CA, Perez RM, Lemos LB, Medina-Pestana JO, Lanzoni VP, Alberto FL,
et al. Factors associated with the intensity of liver ﬁbrosis in renal transplant
patients with hepatitis B virus infection. Eur J Gastroenterol Hepatol
2007;19:653–7.
77. Ridruejo E, Brunet MD, Cusumano A, Diaz C, Michel MD, Jost L, et al. HBsAg as
predictor of outcome in renal transplant patients. Medicina (B Aires)
2004;64:429–32.
78. Chan TM, Fang GX, Tang TS, Cheng IK, Lai KN, Ho SK. Pre-emotive lamivudine
therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
Hepatology 2002;36:1246–52.
79. Morales JM, Dominguez-Gil B, Sanz-Gajardo D, Fernandez J, Escuin F. The
inﬂuence of hepatitis B and hepatitis C virus infection in the recipient on late
renal allograft failure. Nephrol Dial Transplant 2004;19:S72–6.
80. Jeng LB, Huang CC, Lai MK, Chu SH. Hepatocellular carcinoma after kidney
transplantation. Transplant Proc 1999;31:1273–4.
81. Oldakowska-Jedynak M, Durlik M, Paczek L, Zielecka B, Juskowa J, Pawlak J,
et al. Hepatocellular carcinoma development in renal allograft recipients.
Transplant Proc 2000;32:1363–4.
82. McMahon BJ. The inﬂuence of hepatitis B virus genotype and subgenotype on
the natural history of chronic hepatitis B. Hepatol Int 2009;3:334–42.
83. Pol S, Debure A, Degott C, Carnot F, Legendre C, Brechot C, Kreis H. Chronic
hepatitis in kidney allograft recipients. Lancet 1990;335:878–80.
84. Weir MR, Kirkman RL, Strom TB, Tilney NL. Liver disease in recipients of long-
functioning renal allografts. Kidney Int 1985;28:839–44.
85. Rao KV, Anderson WR, Kasiske BL. Value of liver biopsy in the evaluation and
management of chronic liver disease in renal transplant recipients. Am J Med
1993;94:241–50.
86. Afzali B, Al-Khoury S, Shah N, Mikhail A, Covic A, Goldsmith D. Anemia after
transplantation. Am J Kidney Dis 2006;48:519–36.
87. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, et al. Validation of
serum ferritin values by magnetic susceptometry in predicting iron overload
in dialysis patients. Kidney Int 2004;65:1091–8.
88. Herget-Rosenthal S, Gerken G, Philipp T, Holtmann G. Serum ferritin and
survival of renal transplant recipients: a prospective 10-year cohort study.
Transplant Int 2003;16:642–7.
89. Lorenz M, Kletzmayr J, Huber A, Horl WH, Sunder-Plassmann G, Fodinger M.
Iron overload in kidney transplants: prospective analysis of biochemical and
genetic markers. Kidney Int 2005;67:691–7.
90. Bomford A, Williams R. Long term results of venesection therapy in idiopathic
haemochromatosis. Q J Med 1976;45:611–23.
91. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer
G. Survival and causes of death in cirrhotic and noncirrhotic patients with
primary hemochromatosis. N Engl J Med 1985;313:1256–62.
92. Hoffmann CJ, Subramanian AK, Cameron AM, Engels EA. Incidence and risk
factors for hepatocellular carcinoma after solid organ transplantation. Trans-
plantation 2008;86:784–90.
93. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States:
prognostic features, treatment outcome, and survival. Cancer 1996;77:2217–22.
94. Chiang YJ, Wang HH, Liu KL, Chu SH, Lee WC. Hepatocellular carcinoma
following renal transplantation: experience in northern Taiwan. Transplant
Proc 2008;40:2397–9.
95. Tsai MC, Chen CH, Lee CM, Chen YT, Chien YS, Hung CH, et al. The role of
genotype, core promoter and precore mutations in advanced liver disease in
renal transplant recipients. J Hepatol 2009;50:281–8.
96. Pfaff WW, Blanton JW. Hepatitis antigenemia and survival after renal trans-
plantation. Clin Transplant 1997;11:476–9.
97. Ramos EL, Kasiske BL, Alexander SR, Danovitch GM, Harmon WE, Kahana L,
et al. The evaluation of candidates for renal transplantation. Transplantation
1994;57:490–7.
98. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Chronic hepatitis B
virus infection and mortality from non-liver causes: results from the Haimen
city cohort study. Int J Epidemiol 2005;34:132–7.
C.B. Blackadar / International Journal of Infectious Diseases 17 (2013) e24–e36e3699. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular
carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA 2006;295:65–73.
100. Tremblay F, Fernandes M, Habbab F, Edwardes MD, Loertscher R, Meterissian
S. Malignancy after transplantation: incidence and role of type of immuno-
suppression. Ann Surg Oncol 2003;9:785–8.
101. Marcen R, Pascual J, Tato AM, Teruel JL, Villafruela JJ, Fernandez M, et al.
Inﬂuence of immunosuppression on the prevalence of cancer after kidney
transplantation. Transplant Proc 2003;35:1714–6.
102. Hiesse C, Rieu P, Kriaa F, Larue JR, Goupy C, Neyrat N, Charpentier B. Malig-
nancy after renal transplantation: analysis of incidence and risk factors in
1700 patients followed during a 25-year period. Transplant Proc 1997;29:
831–3.
103. Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, Soulillou JP.
Effect of long-term immunosuppression in kidney-graft recipients on cancer
incidence: randomized comparison of two cyclosporine regimens. Lancet
1998;351:623–8.
104. Tur-Kaspa R, Laub O. Corticosteroids stimulate hepatitis B virus DNA, mRNA
and protein production in a stable expression system. J Hepatol 1990;11:34–6.
105. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in
cirrhosis: incidence and risk factors. Gastroenterology 2004;127(Suppl
1):35–50.
106. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissai F, et al. A review of
human carcinogens—part B: biological agents. Lancet Oncol 2009;10:321–2.
107. Villa E, Fattovich G. No inﬂammation? No cancer! Clear HBV early and live
happily. J Hepatol 2010;52:768–70.
108. Preikschat P, Gunther S, Reinhold S, Will H, Budde K, Neumayer HH, et al.
Complex HBV populations with mutations in core promoter, C gene, and pre-S
region are associated with development of cirrhosis in long-term renal
transplant recipients. Hepatology 2002;35:466–77.
109. Rao KV, Kasiske BL, Anderson WR. Variability in the morphological spectrum
and clinical outcome of chronic liver disease in hepatitis B-positive and B-
negative renal transplant recipients. Transplantation 1991;51:391–6.110. Chan TM, Fang GX, Tang TS, Cheng IK, Lai KN, Ho SK. Pre-emptive lamivudine
therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients.
Hepatology 2002;36:1246–52.
111. Vigano M, Colombo M, Aroldi A, Lunghi G, Manenti E, Ponticelli C, Lampertico
P. Long-term lamivudine monotherapy in renal-transplant recipients with
hepatitis-B-related cirrhosis. Antivir Ther 2005;10:709–13.
112. Williams R. Correction of disturbed pathophysiology of hepatic failure by
albumin dialysis. Hepatobiliary Pancreat Dis Int 2008;7:19–24.
113. Hamada T, Kumashiro R, Koga T, Hino T, Furudera S, Sakisaka S, et al. Fatal
acute hepatitis B virus infection while receiving immunosuppressants after
renal transplantation. Intern Med 1993;32:547–51.
114. Sobhonslidsuk A, Sornmayura P, Sumethkul V. Failure of hepatitis B surface
antibody to protect acute fulminating hepatitis in a renal transplant recipient.
J Med Assoc Thai 2006;89(Suppl 2):S257–61.
115. Kharsa G, Degott C, Degos F, Carnot F, Potent F, Kreis H. Fulminant hepatitis in
renal transplant recipients. The role of the delta agent. Transplantation
1987;44:221–3.
116. Peters MG, Singer G, Howard T, Jacobsmeyer S, Xiong X, Gibbs C, et al.
Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B
virus in a renal transplant recipient: durable response after orthotopic liver
transplantation on adefovir dipivoxil and hepatitis B immune globulin. Trans-
plantation 1999;68:1912–4.
117. Ranjan D, Burke G, Esquenazi V, Milgrom M, Koleilat N, Roth D, et al. Factors
affecting the ten-year outcome of human renal graft allografts. Transplantation
1991;51:113–7.
118. Monteon FJ, Gomez B, Valdespino C, Chavez S, Sandoval M, Flores A, et al. The
kidney transplant experience at Hospital de Especialidadea, Centero Medico
Nacional de Occidente, IMSS, Guadalajara Mexico. Clin Transpl 2003;165–74.
119. Touraine JL, Traeger J, LeFrancois N, Pouteil-Noble C, Betuel H, Garnier JL, et al.
Renal transplantation at the University of Lyon. Clin Transpl 1989;229–38.
120. Reddy PN, Sampaio MS, Kuo HT, Martin P, Bunnapradist S. Impact of pre-
existing hepatitis B infection on the outcomes of kidney transplant recipients
in the United States. Clin J Am Soc Nephrol 2011;6:1481–7.
